Bio-Techne Co. (NASDAQ:TECH) Receives Consensus Rating of 'Moderate Buy' from Analysts

As of February 18, 2025, Bio-Techne Co. (NASDAQ:TECH – Get Free Report) is receiving an average recommendation of "Moderate Buy" from a group of seven brokerages that monitor its stock, according to MarketBeat Ratings. This rating is a composite of feedback from various analysts, where two have classified the stock as a hold, while five have endorsed a buy recommendation. The consensus price target set by these brokerages is $86.57 over the next 12 months.

Several research firms have recently updated their ratings and price targets for Bio-Techne. KeyCorp raised its price target from $80.00 to $90.00 and categorized the stock as having an “overweight” rating on February 6th. StockNews.com upgraded Bio-Techne from a “hold” to a “buy” on November 12th. Meanwhile, Robert W. Baird increased their price target from $82.00 to $84.00 and gave the stock an “outperform” rating. Royal Bank of Canada set their price target at $80.00 after raising it from $79.00, and provided a “sector perform” rating. Scotiabank also upped its price target from $88.00 to $90.00, assigning it a “sector outperform” rating.

Insider Trading Activities

In a related matter, CEO Kim Kelderman sold 13,392 shares of Bio-Techne’s stock on January 27th, valued at approximately $1,035,067.68, as the average selling price was $77.29 per share. Following this sale, Kelderman holds 39,004 shares, totaling around $3,014,619.16, representing a 25.56% reduction in his position. The transaction was reported through a filing with the Securities & Exchange Commission, which provides public access to such disclosures. Currently, corporate insiders own 3.90% of Bio-Techne’s stock.

Institutional Investments

Recent shifts in institutional ownership indicate that hedge funds are active in buying and selling Bio-Techne shares. For instance, Mirae Asset Global Investments Co. Ltd. increased its stake by 46.6% in the fourth quarter, now owning 16,650 shares worth $1,215,000 following the purchase of an additional 5,295 shares. Another notable increase came from Assenagon Asset Management S.A., which grew its holdings by 58.8%, holding 43,298 shares valued at around $3,119,000 after an additional 16,038 shares were bought. Moreover, Oddo BHF Asset Management Sas acquired new shares worth approximately $1,188,000 in the third quarter, while Quest Partners LLC and Broadcrest Asset Management LLC also initiated positions during the same period.

Performance Metrics

As for Bio-Techne's stock performance, it opened at $65.94 on Thursday, with a market capitalization of $10.48 billion. Its price-to-earnings ratio stands at 66.61, along with a P/E/G ratio of 5.54 and a beta coefficient of 1.27. The stock’s price history reveals a 52-week low of $61.16 and a high of $85.57, alongside fifty and two-hundred-day moving averages of $73.59 and $73.73 respectively. The company’s solvency ratios reflect a debt-to-equity ratio of 0.14, a quick ratio of 3.26, and a current ratio of 3.94.

Latest Earnings Report

Bio-Techne published its quarterly earnings on February 5th, reporting earnings per share (EPS) of $0.35, which fell short of the anticipated $0.38 by $0.03. The firm noted a net margin of 13.22% and a return on equity of 12.73%. Analysts predict that Bio-Techne is expected to report an EPS of 1.68 for the ongoing fiscal year.

Dividend Announcement

The company also recently revealed a quarterly dividend, set to be paid on February 28th, for stockholders on record by February 17th. This dividend is valued at $0.08 per share, amounting to an annualized dividend of $0.32, which equates to a yield of 0.49%. The ex-dividend date was noted as February 14th, and Bio-Techne's dividend payout ratio currently stands at 32.32%.

Company Overview

Bio-Techne Corporation, along with its subsidiaries, focuses on developing, manufacturing, and selling life science reagents, instruments, and services tailored for research and clinical diagnostic applications across various markets, including the United States and several regions worldwide.

Bio-Techne, Stock, Recommendation